Phase 3 Trial Initiation for KER-007
Resolves: FDA acceptance of Phase 3 trial protocol for KER-007
sec_filing· Regulatory Filings
Phase 3 Trial Initiation for KER-007
Market overview
Derived from Keros Therapeutics, Inc. (KROS) (CIK 0001664710) 8-K filing analysis
Regulatory Filings prediction market
- Implied probability (Yes)
- 85%
- Closes
- 2027-03-31
About this prediction
Resolution criteria
FDA acceptance of Phase 3 trial protocol for KER-007
More Regulatory Filings markets
- Related Regulatory Filings — 40% Yes
- Bitwise Bitcoin ETF 2026 Annual Filing — 95% Yes
- Post-Merger Regulatory Approvals — 60% Yes
- FDA approval for new drug candidate — 75% Yes
- Completion of Regulatory Filings for Acquisition — 85% Yes
- Timely Filing of 2026 10-K Report — 95% Yes
- Phase 3 Interim Data Readout — 55% Yes
- Silexion Therapeutics Potential IND/NDA Filing — 70% Yes
No one's made a Conviction call on this yet. Be the first to call it →
Loading…